Please use this identifier to cite or link to this item:
Title: Evaluation of the use of amphipathic peptide-based protein carrier for in vitro cancer research
Authors: Lo, S.L.
Wang, S. 
Keywords: Drug delivery system
Self assembly
Issue Date: 9-Mar-2012
Citation: Lo, S.L., Wang, S. (2012-03-09). Evaluation of the use of amphipathic peptide-based protein carrier for in vitro cancer research. Biochemical and Biophysical Research Communications 419 (2) : 170-174. ScholarBank@NUS Repository.
Abstract: Intracellular delivery of proteins offers an alternative to genetic modification or siRNA transfection for functional studies of proteins in live cells, especially for studies in cancer cells for therapeutics development. However, lack of efficient and biocompatible delivery system has limited the use of protein for in vitro cancer research. In this study, we design and evaluate an amphipathic peptide RV24, composing of a hydrophobic domain for protein binding, a flexible linker, and a hydrophilic domain to facilitate cell penetration. When using β-galactosidase as a cargo protein for comparison with commercially available peptide- and lipid-based carriers, RV24 peptide provides up to 5-fold increase in quantity delivered into 3 different cancer cell lines. Green fluorescent protein could also be delivered rapidly within 4. h and transduced up to 83% of tested cancer cell lines. Although having a cell penetrating domain, RV24 peptide did not compromise cell viability, morphology and granularity significantly. These findings suggest the feasibility of using biocompatible amphipathic peptide to efficiently deliver protein-based molecules intracellularly for in vitro cancer research. © 2012 Elsevier Inc.
Source Title: Biochemical and Biophysical Research Communications
ISSN: 0006291X
DOI: 10.1016/j.bbrc.2012.01.134
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.